We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Apheresis System with Secondary Devices Evaluated

By LabMedica International staff writers
Posted on 06 Jun 2017
Therapeutic plasma exchange (TPE) reduces the levels of pathological factors circulating in the patient’s plasma and it relieves symptoms or prevents further destruction of the involved organ or system.

As an alternative to TPE, specific plasma purification methods such as lipoprotein apheresis or immunoadsorption have been developed for selective removal of the purported pathological substances from the separated plasma.

Scientists at the University Hospital Jena (Germany) examined the last 300 data log files from November 2015 until October 2016. More...
Of these 300 procedures, 149 secondary plasma treatments were conducted in 13 patients, 76 immunoadsorption (IA) and 73 lipoprotein apheresis (LA). Nine patients had IA due to transplantation and autoimmune diseases. Four patients were treated with LA after heart transplantation. Of the procedures, 62% were performed using peripheral venous access, even in patients with a low inlet blood flow.

All patients were treated with the Spectra Optia Apheresis System. An adsorption matrix, Immunosorba, was used for IA, and the Fresenius Medical Care Monet or Evaflux was used for LA. The immunoadsorption (IA) columns need an additional device for secondary plasma processing. Adasorb devices allow adsorption and desorption (regeneration) of the columns. In one session, the device treats up to 10,000 mL of plasma.

A central catheter was required only in 15% cases, and an arteriovenous fistula in 23% of the procedures. Anticoagulation management differed in both procedures. The LA procedures required a higher amount of citrate as they were performed using only citrate. The IA procedures required less citrate because a mixture of citrate and heparin was used. The scientists did not observe clotting or bleeding, regardless of heparin use. Due to strict calcium management, no patient showed signs of hypocalcemia. They found that the targeted substances could be reduced significantly: lipoprotein (a) (Lpa) level by 68%, low-density lipoprotein-cholesterol by 57%, and immunoglobulin G (IgG) from 6.6 to 2.61 g/L.

The authors concluded that the Spectra Optia had a high plasma extraction efficiency, which allows secondary plasma device procedures with peripheral venous access and moderate inlet flow rates. One of the biggest advantages of the Optia is its high plasma removal efficiency. Ideal plasma flow rates for filter or IA columns could be reached faster. The study was published on May 24, 2017, in the International Journal of Clinical Transfusion Medicine.

Related Links
University Hospital Jena


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image Credit: iStock

Global TB Summit Connects Diagnostic Testing With Prevention and Clinical Care

Tuberculosis remains a major global infectious disease challenge despite declining deaths. In 2024, an estimated 10.7 million people worldwide developed the disease and nearly 1.2 million died from it.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.